Paul Eckburg - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Medical Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Paul Eckburg
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:25:06 UTC
Next filing
16 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ANTX Common 18,289 24 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 4,418 $0.4200 Direct F1
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 118,999 $6.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and exercisable.
F2 The shares subject to the option vest as follows: 25% of the shares shall vest on April 30, 2022; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.

Remarks:

Exhibit 24 - Power of Attorney